Skip to content
OpenCapital
Get started

Immunome IMNM Acquired in-process research and development

Acquired in-process research and development at other companies

Exelixis logo
ExelixisEXEL
$2.03M—
Eli Lilly logo
Eli LillyLLY
$584M-62.8%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0×0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's acquired in-process research and development?
Immunome (IMNM) reported acquired in-process research and development of $9.01M in Q1 2026.
How has Immunome's acquired in-process research and development changed year-over-year?
Immunome's acquired in-process research and development increased by 44.3% year-over-year, from $6.25M to $9.01M.
What does acquired in-process research and development mean?
This represents the actual cash outflow associated with the acquisition of in-process research and development assets from third parties. Unlike non-cash charges, this metric tracks the deployment of capital to secure external innovation pipelines. It is a critical indicator of a company's strategy to supplement internal R&D with external intellectual property.